Emerging Company Profile

Inotek: Fighting radicals

Free radicals, or reactive oxygen species, carry an unpaired electron and can damage DNA. While other companies have focused on ways to reduce levels of oxidants or free radicals to treat a range of diseases, Inotek Corp. believes that its focus on later stages in the cellular damage pathway mediated by these molecules will prove to be more successful.

"These mechanisms are generic, and are broadly represented in a large spectrum of diseases," said Andrew Salzman, president and CEO. "It's a platform technology based on an important pathophysiological mechanism. Our approach is to focus on the end effector mechanisms of injury, since patients present already along in their disease course."